secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalo Therapeutics, Inc. (AVTX)
CIK:        0001534120
Form:       8-K
Filed at:   2026-06-23T11:01:57+00:00
Accession:  0001534120-26-000044
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Avalo Therapeutics appoints Ron Philip to Board of Directors
------------------------------------------------------------

- Ron Philip appointed to board effective June 23, 2026; will serve until 2027 annual meeting.
- Appointed to Compensation Committee and Science, Development and Commercial Advisory Committee.
- Received non-qualified stock option to purchase 40,200 shares, vesting over 3 years.
- Mr. Philip most recently was CEO of Orbital Therapeutics until its acquisition by Bristol-Myers Squibb in Dec 2025.
- Board determined Mr. Philip satisfies Nasdaq independence standards.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534120/000153412026000044/0001534120-26-000044-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534120/000153412026000044/avtx-20260623.htm
  HTML page:      https://secwatch.observer/filing/0001534120-26-000044

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer